<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1391">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01784900</url>
  </required_header>
  <id_info>
    <org_study_id>2012-000475-17</org_study_id>
    <secondary_id>2011/1793</secondary_id>
    <nct_id>NCT01784900</nct_id>
  </id_info>
  <brief_title>Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab</brief_title>
  <acronym>IIPOP</acronym>
  <official_title>Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab. A Randomized Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment by association of complete surgical excision of the lesions and intraperitoneal
      immunotherapy using Catumaxomab for patients with gastric peritoneal carcinomatosis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>every 3 months for the first two years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>every 3 months for the first two years then every 4 months on year 3 then every 6 months on year 4 and 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Patients With Gastric Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Schema B (140µg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Schema A (100µg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Catumaxomab 100µg</intervention_name>
    <arm_group_label>Schema A (100µg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Catumaxomab 140µg</intervention_name>
    <arm_group_label>Schema B (140µg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  consent form signed

          -  Age &gt;= 18

          -  Carcinomatosis pre operative known or discivered in intraoperative

          -  Patients uin good general condition who may have extent surgery associated to
             specific inflammatory syndrom of immunotherapy

          -  Patient insured to social care

        Inclusion Criteria (intraoperative):

          -  Gastric adenocarcinoma with macroscopic peritoneal carcinomatosis (PC) confirmed by
             extemporaneous histological examination

          -  CP extension minimal or moderate (peritoneal index ≤ 12).

          -  Resection of the entire macroscopic lesions detectable (primary tumor, lymph nodes
             and CP). cleaning D2 lymph node (or D1.5).

        Exclusion Criteria:

          -  Presence of metastasis in reach

          -  Previous treatment with a non-humanized monoclonal AC- (mice or rat)

          -  Hypersensitivity to any type of antibody.

          -  History of cancer within 5 years preceding the entry in the trial other than basal
             cell skin carcinoma or in situ of the cervix,

          -  Patients already included in another clinical trial with experimental molecule

          -  Pregnant, or likely to be or breastfeeding, (Women of childbearing potential should
             have a pregnancy test (blood) negative 15 days before the date of the surgery) Using
             of a suitable method of contraception for patients of childbearing age during
             treatment. adequate contraception Methods includeare: an intrauterine device,
             hormonal contraception, condom use combined with a spermicide

          -  Persons deprived of liberty or Trust (including curatorship)

          -  Unable to undergo medical test for geographical, social or psychological.

        Exclusion Criteria (intraoperative):

          -  Persistent peritoneal lesions visible to the end of the surgery

          -  Resection of the tail of the pancreas or pancreatic break (because no drainage
             post-op); break pleural (for K cardia)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ELIAS Dominique, MD</last_name>
    <phone>142114085</phone>
    <phone_ext>+33</phone_ext>
    <email>dominique.elias@igr.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>PARLAVECCHIO Cedric</last_name>
    <phone>142113465</phone>
    <phone_ext>+33</phone_ext>
    <email>cedric.parlavecchio@igr.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ELIAS Dominique, MD</last_name>
      <phone>142114085</phone>
      <phone_ext>+33</phone_ext>
      <email>dominique.elias@igr.fr</email>
    </contact>
    <contact_backup>
      <last_name>PARLAVECCHIO Cedric</last_name>
      <phone>142113465</phone>
      <phone_ext>+33</phone_ext>
      <email>cedric.parlavecchio@igr.fr</email>
    </contact_backup>
    <investigator>
      <last_name>ELIAS Dominique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <lastchanged_date>February 5, 2013</lastchanged_date>
  <firstreceived_date>February 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
